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. Second, despite more than three decades of intensive effort, no effective pharmacological inhibitor of the RAS oncoprotein has reached the clinic. So it is exciting that, on page 638 of this issue, Zimmermann et al. 2 report* the identification and characterization of a small-molecule inhibitor that interferes with the localization of KRAS -the RAS isoform most commonly mutated in human cancers -to the plasma membrane surrounding cells 3 . Following their synthesis in the cytoplasm, RAS proteins are initially inactive 4 . They then undergo a series of rapid post-translational modifications that ensure their association with the inner leaflet of the plasma membrane, where these proteins exert their normal, as well as their cancer-associated, signalling activity. Therefore, most efforts aimed at anti-RAS drug discovery have involved indirect approaches to block the activities of proteins that either promote plasma-membrane association of RAS or are components of its downstream signalling pathway.
The key post-translational modification of RAS involves the addition of a 15-carbon farnesyl lipid tail in a reaction catalysed by the farnesyltransferase enzyme. This modification facilitates RAS association with membranes and is essential for proper RAS localization and activity, having prompted intensive efforts in the 1990s to develop farnesyltransferase inhibitors (FTIs).
Despite promising results in preclinical studies, however, the results of clinical trials with FTIs were disappointing. The inhibitors blocked membrane association of the HRAS isoform, but lacked antitumour activity in cancers involving mutated KRAS (and NRAS). KRAS could still associate with the plasma membrane through an unexpected compensatory activity of the farnesyltransferase-related enzyme geranylgeranyltransferase-I, which modifies RAS with a geranylgeranyl, rather than a farnesyl, group. This discouraging outcome greatly dampened interest in targeting RAS -and, in particular, its membrane association -for cancer treatment. Instead, on going efforts have mainly focused on inhibitors of the RAF-MEK-ERK and the PI3K-AKT signalling cascades downstream of RAS.
Zimmermann et al. describe an approach aimed at disrupting KRAS membrane association that warrants reassessment of the current strategies. The authors identify and characterize a small-molecule inhibitor of PDEδ, a protein that can bind to and regulate the trafficking of RAS and RAS-related proteins to membrane compartments [5] [6] [7] [8] used to form the next link of the chain.
Additionally, mammalian Ubc9 forms an extremely stable complex with RanBP2, a nuclear-pore protein 8 . This complex acts as a composite E3 enzyme: the RanBP2-bound Ubc9 has a structural role, with a second Ubc9 catalysing isopeptide-bond formation between SUMO and its target protein. Intriguingly, the rear surface of Ubc9 that is stably bound to RanBP2 does not seem to be exposed, and so the orientation of the two Ubc9 molecules associated with RanBP2 probably differs from the arrangement of paired Ubc9 molecules described by Klug and colleagues. Collectively, these mechanisms suggest that E2 enzymes can be adapted for a variety of structural roles in conjugation pathways, and they hint that many more variations on this theme will be found.
Klug and co-authors also investigated the significance of Ubc9 SUMOylation during meiosis -the process by which a parental cell containing two sets of chromosomes eventually divides into four daughter cells, each carrying a single chromosome set. Yeast cells containing a Ubc9 mutant that could not be SUMOylated failed to form a synaptonemal complex, a meiotic structure that promotes both genetic exchange between chromosome pairs and correct chromosome segregation to daughter cells. In these mutants, individual components of the synaptonemal complex showed altered concentrations as well as faulty incorporation into the complex. These findings build on earlier results 9 to indicate that the formation of SUMO chains is necessary for the synaptonemal complex to function, although many details of the meiotic defect remain unclear.
The same Ubc9 mutants grew normally under all the non-meiotic conditions that Klug et al. tested, and showed no increased sensitivity to stress conditions. This may imply either that normal growth and stress responses do not require polySUMOylation levels as high as those needed for meiosis, or that other mechanisms for achieving polySUMOylation can be invoked and are sufficient outside meiosis. The researchers note that wild-type Ubc9 becomes increasingly SUMOylated during meiosis, and it will be interesting to discover how this 'autoSUMOylation' is triggered to promote the polySUMOylation of downstream targets.
Ubc9 is the sole E2 enzyme in the SUMO pathway and so can act as a key regulatory point under circumstances in which the overall pattern of SUMOylation fluctuates in response to varying cellular conditions 10, 11 . Although different consequences of autoSUMOylation on different domains of mammalian Ubc9 have been described 5 to perform a high-throughput screen to identify small molecules that could block PDEδ association with the farnesylated tail of KRAS. After identifying several hits, they took a structure-based drugdesign approach to develop their most promising compound, designated deltarasin. The researchers' fluorescence microscopy experiments validate deltarasin's ability to block PDEδ-KRAS interaction in live cells. Following addition of 5-micromolar deltarasin to human KRAS-mutant pancreatic-cancer cell lines, PDEδ could no longer redistribute KRAS to the plasma membrane. Deltarasin also impaired the proliferative capacity of the pancreatic-cancer cell lines, which depends on signalling of mutant KRAS. Furthermore, it greatly reduced KRAS-dependent signalling events, such as phosphorylation of the ERK1 and ERK2 proteins. When the authors assessed the effects of deltarasin in vivo, in a mouse model of pancreatic ductal adenocarcinoma, they observed a dose-dependent reduction in tumour growth.
Recently, there has been a resurgence of interest in targeting RAS. This is due in part to the findings of cancer-genomics studies, which have reaffirmed KRAS mutations as the predominant oncogenic abnormalities in several cancers, including pancreatic, lung and colorectal cancers. However, the task of blocking mutant KRAS function with anti cancer drugs remains daunting, requiring identification of fresh strategies. Zimmermann and colleagues' finding, that pharmacologically disrupting the ability of PDEδ to promote plasma-membrane association of KRAS impairs the growth of KRAS-mutant pancreatic tumour cells, points to a provocative and innovative approach that may succeed where FTIs failed (Box 1).
Indeed, the efficacy of a PDEδ inhibitor will not be circumvented by alternative prenylation mechanisms, such as geranylgeranylation, that prevent FTIs from blocking KRAS (and NRAS) association with the plasma membrane. Nonetheless, as is the case with FTIs, inhibition of RAS regulation by PDEδ will probably have unforeseen consequences. PDEδ can interact with other farnesylated proteins, including farnesylated RAS-family proteins that act as tumour suppressors (for example, NOEY2, also called DiRAS3). Inhibition of such beneficial proteins may lead to toxic effects in normal cells.
There are also conflicting observations regarding PDEδ selectivity for farnesylated and geranylgeranylated proteins 6 . If PDEδ is also required for the trafficking of geranylgeranylated proteins (such as Rho proteins), then additional off-target effects may be seen.
Another unresolved issue is exactly how dependent RAS proteins are on PDEδ for proper localization, because even in the absence of PDEδ, KRAS can bind to cell membranes 8 . That KRAS deficiency is lethal, whereas PDEδ deficiency is not 9 , underscores the fact that at least some KRAS functions are PDEδ independent. So, although Zimmermann and co-authors' data are exciting, much remains to be learnt about PDEδ function and mutant-RAS dependency on it for proper subcellular localization. Inhibitors of the RAS signalling pathway
